Clinical Trial Update: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Regor Pharmaceuticals is conducting a Phase 1 trial of RGT-419B alone and in combination with endocrine therapy for HR-positive, HER2-negative advanced or metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RGT-419B

Snippet

Sponsor: Regor Pharmaceuticals Inc. | Conditions: Breast Cancer | Phase 1 | Status: RECRUITING